Harvoni (Ledipasvir, Sofosbuvir)

Harvoni is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, either as a standalone regimen or in combination with other antiviral agents when appropriate.

• Patients infected with HCV genotype 1 (including subtypes 1a and 1b), regardless of prior treatment status.
• Individuals diagnosed with HCV genotype 4 infection, which is prevalent in certain regions of the Middle East and Africa.
• Adults with chronic HCV genotype 5 infection, a less common genotype found primarily in South Africa.
• Patients harboring HCV genotype 6 infection, which is more frequently observed in Southeast Asia.
• Those with compensated cirrhosis who meet specific clinical criteria, allowing use of Harvoni without ribavirin.

Harvoni may cause a range of side effects, most of which are mild to moderate and resolve without intervention. The frequency and severity of these events vary among individuals.

Common

• Fatigue or a feeling of tiredness that may affect daily activities.
• Headache, ranging from mild to moderate intensity.
• Nausea or an upset stomach, sometimes accompanied by loss of appetite.
• Diarrhea, which is usually mild and transient.

Serious

• Severe allergic reaction, including rash, itching, swelling of the face or throat, or difficulty breathing, which requires immediate medical attention.
• Significant elevations in liver enzymes (ALT/AST) indicating possible liver injury, especially in patients with pre‑existing liver disease.

When prescribing Harvoni, clinicians should consider several precautions to ensure safe and effective use.

• Assess liver function before initiating therapy, especially in patients with cirrhosis.
• Monitor for potential drug–drug interactions, as Harvoni is metabolized via hepatic pathways.
• Use caution in patients with renal impairment; dose adjustment may be required for co‑administered agents.
• Counsel women of childbearing potential about contraception, as pregnancy category B indicates limited data.
• Discontinue or adjust therapy if severe adverse reactions such as allergic reactions or significant liver enzyme elevations occur.

Harvoni can interact with other medications; understanding these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Strong inducers of CYP3A4 such as rifampin, carbamazepine, and phenytoin, which may lower Harvoni plasma levels.
• Antiretroviral agents like efavirenz that significantly reduce drug exposure.
• Concomitant use of certain HIV protease inhibitors (e.g., ritonavir) may increase sofosbuvir exposure and requires monitoring.

Use with caution

• Amiodarone, due to the risk of serious bradycardia when combined with Harvoni.
• Certain statins (e.g., simvastatin, lovastatin) that may increase statin concentrations.
• Proton pump inhibitors (e.g., omeprazole) that can reduce ledipasvir absorption.
• Herbal supplements such as St. John’s wort, a CYP3A4 inducer, may reduce Harvoni effectiveness.